Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor)
Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m. Eastern
REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will present new clinical data for two of its RAS(ON) Inhibitors and other investigational compounds at upcoming oncology conferences, the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ("Triple Meeting") in Boston, Massachusetts, to be held October 11-15, and the 2023 European Society for Medical Oncology Congress (ESMO) in Madrid, Spain, to be held October 20-24.
At the Triple Meeting, the company will present the first report of clinical activity for RMC-6291, its RASG12C(ON) Inhibitor and additional preliminary safety and pharmacokinetic profiles for RMC-6236, its RASMULTI(ON) Inhibitor. At ESMO, the company will present additional preliminary antitumor activity data for RMC-6236 in patients with non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC) carrying common KRASG12X mutations. The abstract related to this presentation, which will go live on the ESMO website at 0:05 CEST on October 16, 2023 (6:05 p.m. ET, October 15), will include data from an April 24, 2023 data extraction, while the Proffered Paper presentation itself will include more recent data from an October data extraction.
Shortly following the company's ESMO data presentation, the company will host an investor webcast to review the clinical data presentations on RMC-6236 and RMC-6291, related clinical development vision, and the company's overall pipeline and strategy.
Details of the presentations referenced above, as well as other presentations by the company at these conferences, are listed below:
Triple Meeting Oral Presentations:
Title: | Targeting RAS-addicted cancers with investigational RAS(ON) inhibitors |
Presenter: | W. Clay Gustafson, M.D. |
Session: | Plenary Session 3: KRAS |
Date/Time: | 8:00 – 9:40 a.m. ET on October 13, 2023 |
Title: | Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001 |
Presenter: | Alexander I. Spira |
Abstract Number: | B032* |
Session: | Plenary Session 4: ... |